US.CRL · Charles River Laboratories

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 4.04334010062671,
        "turnoverUsdM": 107.874738,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 208.2572,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 8.1,
      "take_profit_price": 238.5509,
      "target_multiplier": 1.6,
      "technical_strength": 1.22,
      "take_profit_percent": 5.3
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 8.08668020125342,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 59,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 52,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 226.7665,
    "ma50": 196.691,
    "close": 226.58,
    "prevClose": 229.29,
    "avgVolume20": 879625,
    "volumeRatio": 0.54,
    "changePercent": -1.18
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.00993978114821581,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.510497308657331,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.808387440419162,
      "volat_points": 0,
      "day_range_pct": 0.03067349721952505,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 59,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 7,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 46.67,
        "contribution": 7
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 5.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 57,
        "contribution": 5.7
      },
      {
        "raw": 18.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 62,
        "contribution": 18.6
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 52,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 7/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 5.7/10分",
      "技術信號分析總分: 18.6/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 1.5,
      "資金流": 9.2,
      "市場環境": 7,
      "情緒分析": 4,
      "技術信號": 18.6,
      "風險管理": 5.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 107.874738,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.7
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 711.71300025,
                "ma50": 718.2872022,
                "name": "QQQ",
                "close": 684.22998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.1530053500001,
                "ma50": 745.0680014400001,
                "name": "SPY",
                "close": 738.92999,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 4.04334010062671,
          "atrPoints": 2,
          "cciPoints": 2.4,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140958949,
                "url": "https://finnhub.io/api/news?id=83f112067729714753fb3875eb02ff2510b1f1356cc8d88c75257607a7431130",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1784548900,
                "headline": "CLSA Downgrades Charles River Laboratories International (CRL)"
              },
              {
                "id": 140934681,
                "url": "https://finnhub.io/api/news?id=0d7e83486c89d222dc3769dce586a3573c6f9a41f644d03e12aeac2bacb11eca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1784304002,
                "headline": "What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?"
              },
              {
                "id": 140929134,
                "url": "https://finnhub.io/api/news?id=c3039391183d169d5c29150bc2a1a61ab957c8d50c62c553e1522fc8ecb05e8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (CRL) has drawn fresh investor attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, an off the shelf CAR-iNKT cell therapy program. See our latest analysis for Charles River Laboratories International. The collaboration news comes as Charles River Laboratories International trades at US$229.16, with a 30 day share price return of 24.01% and a 1 year total shareholder...",
                "category": "company",
                "datetime": 1784262794,
                "headline": "Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?"
              },
              {
                "id": 140919042,
                "url": "https://finnhub.io/api/news?id=0c3cc32b0ac58d975eb0f821b41df81be9995c1abaf3bddd6b064d60b4e23d7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "In July 2026, Arovella Therapeutics announced a collaboration with Charles River Laboratories International to provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing in support of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. The partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...",
                "category": "company",
                "datetime": 1784196692,
                "headline": "Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?"
              },
              {
                "id": 140900063,
                "url": "https://finnhub.io/api/news?id=082e4e979ef332876504bc052995c8027281c32622380f6499f371a90f1f3c83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784045405,
                "headline": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140807120,
                "url": "https://finnhub.io/api/news?id=0be1ab71065229cd12c18938420ca1ea0de7dd33e244110c4477fa182d790fb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) is one of the top stocks to buy according to Ariel Investments. On June 17, Morgan Stanley upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to an Overweight from Equalweight and raised the price target to $220 from $185. The research firm remains bullish on the company’s long-term prospects and […]",
                "category": "company",
                "datetime": 1783172190,
                "headline": "Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?"
              },
              {
                "id": 140794225,
                "url": "https://finnhub.io/api/news?id=87afbbdfa3cf90f6fa9c2f1606b8e4e2815a41965d06fb3a2e23ca6b6f724d0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P 500 has gained 9.3%.",
                "category": "company",
                "datetime": 1783019304,
                "headline": "3 Reasons to Avoid CRL and 1 Stock to Buy Instead"
              },
              {
                "id": 140782807,
                "url": "https://finnhub.io/api/news?id=67d747b0e4de7ac62347615064d2cb439961b24f91a7a1a938f941d01938ecdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "LH vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782920405,
                "headline": "LH or CRL: Which Is the Better Value Stock Right Now?"
              }
            ],
            "raw_source": [
              {
                "id": 141007898,
                "url": "https://finnhub.io/api/news?id=4e1b2df29b10a81eb5b7242e1dd9bf833179ad3e79e293a12a1feb8308f4a946",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.",
                "category": "company",
                "datetime": 1784908020,
                "headline": "HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised"
              },
              {
                "id": 140993990,
                "url": "https://finnhub.io/api/news?id=5206b71e1b095efb2af34273688ebb056f5dbbce6ba73d7fae75c33032ce9e3b",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1784817301,
                "headline": "Which S&P500 stocks are gapping on Thursday?"
              },
              {
                "id": 140994691,
                "url": "https://finnhub.io/api/news?id=7e710b46240704d0856571ac4bd9402c25d758a8f076a5178cab331d2433d515",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Featuring Thermo Fisher Scientific, Agilent Technologies, Merck, Eurofins Scientific, Charles River Labs and Other Key Players In Vitro Toxicology Testing Market In Vitro Toxicology Testing Market Dublin, July 23, 2026 (GLOBE NEWSWIRE) -- The \"In Vitro Toxicology Testing Market by Product, Toxicity Endpoints & Type, Technology, Method, Service, Region, Competition - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. The global in vitro toxicology testing market is proj",
                "category": "company",
                "datetime": 1784815740,
                "headline": "In Vitro Toxicology Testing Market to Exceed $20.97 Billion by 2031 as Non-Animal Testing & AI Adoption Accelerate - Analysis by Product, Toxicity Endpoints & Type, Technology, Method, Service, Region"
              },
              {
                "id": 140992858,
                "url": "https://finnhub.io/api/news?id=fc6e06457fb216266ed7ade2993afcedbedc6648f41f9685a003e7793ce61b00",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.",
                "category": "company",
                "datetime": 1784810101,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Thursday."
              },
              {
                "id": 140991948,
                "url": "https://finnhub.io/api/news?id=ae1d2bbe081800c547c59869089aef05b744dd00f73df2d086d3c0fb23642b3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1784794849,
                "headline": "3 Profitable Stocks with Warning Signs"
              },
              {
                "id": 140983399,
                "url": "https://finnhub.io/api/news?id=8394ac7825877880e4f6f9b9006d41b558dd12919524e1eec0b7f0c68a7d97fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 10.2% over the past six months while the S&P 500 was up 7.7%.",
                "category": "company",
                "datetime": 1784729187,
                "headline": "3 Healthcare Stocks We Approach with Caution"
              },
              {
                "id": 140961419,
                "url": "https://finnhub.io/api/news?id=d637934a79a18f0fbb5960f741f6b23332bad7d4c8cea1f1b5a337a6b4684e21",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1784565301,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 140964977,
                "url": "https://finnhub.io/api/news?id=91757da27d905adfa467e3b6268971b5d3137a3598c3aac6b41924b8129c733e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
                "category": "company",
                "datetime": 1784562231,
                "headline": "Charles River Laboratories Earnings Preview: What to Expect"
              },
              {
                "id": 140958949,
                "url": "https://finnhub.io/api/news?id=83f112067729714753fb3875eb02ff2510b1f1356cc8d88c75257607a7431130",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1784548900,
                "headline": "CLSA Downgrades Charles River Laboratories International (CRL)"
              },
              {
                "id": 140934681,
                "url": "https://finnhub.io/api/news?id=0d7e83486c89d222dc3769dce586a3573c6f9a41f644d03e12aeac2bacb11eca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1784304002,
                "headline": "What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?"
              },
              {
                "id": 140929134,
                "url": "https://finnhub.io/api/news?id=c3039391183d169d5c29150bc2a1a61ab957c8d50c62c553e1522fc8ecb05e8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (CRL) has drawn fresh investor attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, an off the shelf CAR-iNKT cell therapy program. See our latest analysis for Charles River Laboratories International. The collaboration news comes as Charles River Laboratories International trades at US$229.16, with a 30 day share price return of 24.01% and a 1 year total shareholder...",
                "category": "company",
                "datetime": 1784262794,
                "headline": "Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?"
              },
              {
                "id": 140922751,
                "url": "https://finnhub.io/api/news?id=064695c2c7c73e8c795a57647a68b4874cbf622ad91f18be92ec15c915686b53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.",
                "category": "company",
                "datetime": 1784217000,
                "headline": "Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market"
              },
              {
                "id": 140921387,
                "url": "https://finnhub.io/api/news?id=354c75e1ea8127553c95abb7c927110b41672229afc0a5e5075f2b7293626180",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1784209202,
                "headline": "Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 140919042,
                "url": "https://finnhub.io/api/news?id=0c3cc32b0ac58d975eb0f821b41df81be9995c1abaf3bddd6b064d60b4e23d7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "In July 2026, Arovella Therapeutics announced a collaboration with Charles River Laboratories International to provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing in support of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. The partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...",
                "category": "company",
                "datetime": 1784196692,
                "headline": "Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?"
              },
              {
                "id": 140908618,
                "url": "https://finnhub.io/api/news?id=a4686923cf2ae0bccc68715c5dd217f0a93027deba81200c594746b5ef65c208",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., July 15, 2026--Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call",
                "category": "company",
                "datetime": 1784116800,
                "headline": "Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call"
              },
              {
                "id": 140906904,
                "url": "https://finnhub.io/api/news?id=26ba1d6140c24baf0244169fcb31d4e7b0736e23a09e8f714aca89acedb29364",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities span cytotoxicity, phenotypic and morphological assays, flow cytometry, and pharma and biotech demand. Asia-Pacific and Europe expansion, rare-disease models, single-cell services, and patient-derived and cardiac organoid platforms offer further potential. Cell-Based Assay Services for Preclinical Use Only Market Cell-Based Assay Services for Preclinical Use Only Market Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The \"Cell-Based Assay Services for Preclinical Use Only Global Market O",
                "category": "company",
                "datetime": 1784107500,
                "headline": "Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released — Profiles Charles River, Labcorp, Eurofins and Evotec"
              },
              {
                "id": 140900063,
                "url": "https://finnhub.io/api/news?id=082e4e979ef332876504bc052995c8027281c32622380f6499f371a90f1f3c83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1784045405,
                "headline": "Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140885104,
                "url": "https://finnhub.io/api/news?id=fd0b1d464794cb1451526eb0971ba78dc64e37b2409910a9701810fb2f4d9d7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., July 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA app",
                "category": "company",
                "datetime": 1783944000,
                "headline": "Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches"
              },
              {
                "id": 140886507,
                "url": "https://finnhub.io/api/news?id=a8b2c8f3e5e344f2a19f19bcb2204a6733a8d0ebc0ff3860ce7fd67951f1bc98",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Beijing--China---June-4--2023-Keysight-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.",
                "category": "company",
                "datetime": 1783930266,
                "headline": "Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday"
              },
              {
                "id": 140892086,
                "url": "https://finnhub.io/api/news?id=eebeaa97f43d4d52fa7c0a3f4e664b6419720762ccd693470e58e358003eafb6",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Mizuho  analyst Ann Hynes   maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $192 to $230.",
                "category": "company",
                "datetime": 1783926070,
                "headline": "Mizuho Maintains Neutral on Charles River, Raises Price Target to $230"
              },
              {
                "id": 140856250,
                "url": "https://finnhub.io/api/news?id=b9f7a3fee30a908a0206951371fbb4d8ce5eb3f8f2dac600d176f8a49f8d557a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Morgan Stanley  analyst Ricky Goldwasser   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $220 to $260.",
                "category": "company",
                "datetime": 1783600751,
                "headline": "Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $260"
              },
              {
                "id": 140844609,
                "url": "https://finnhub.io/api/news?id=06debdbe96e5a3379434f0d812c343f6aedc7cf9a24b24158b5f6af43a5df122",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "ICLR is tapping CRO demand, AI workflows and wider trial access, but uneven revenue trends and margin resets keep its earnings recovery in focus.",
                "category": "company",
                "datetime": 1783534140,
                "headline": "ICON Stock and the CRO Trends Shaping Its Next Growth Phase"
              },
              {
                "id": 140831666,
                "url": "https://finnhub.io/api/news?id=b42db579b28559beb0c3dd7036e41c5bf5256c1ebd275e54eaa52f4f1cd19a5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.",
                "category": "company",
                "datetime": 1783432320,
                "headline": "Medpace Growth Trends Show How CRO Demand Is Shifting in 2026"
              },
              {
                "id": 140829250,
                "url": "https://finnhub.io/api/news?id=376a5f774e3a7b2329a07adfaae7e4c5cf120d607ca50f7367fc06a8aa4cda40",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
                "category": "company",
                "datetime": 1783424272,
                "headline": "3 Overrated  Stocks We’re Skeptical Of"
              },
              {
                "id": 140821257,
                "url": "https://finnhub.io/api/news?id=965c970ee9bc1c880a7ae424ce53bb3ac5e36a3c41f0c0a4849e290c54a19678",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.",
                "category": "company",
                "datetime": 1783346400,
                "headline": "Medpace Stock Outlook Turns on Backlog Quality and Cancellations"
              },
              {
                "id": 140807120,
                "url": "https://finnhub.io/api/news?id=0be1ab71065229cd12c18938420ca1ea0de7dd33e244110c4477fa182d790fb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) is one of the top stocks to buy according to Ariel Investments. On June 17, Morgan Stanley upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to an Overweight from Equalweight and raised the price target to $220 from $185. The research firm remains bullish on the company’s long-term prospects and […]",
                "category": "company",
                "datetime": 1783172190,
                "headline": "Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?"
              },
              {
                "id": 140794225,
                "url": "https://finnhub.io/api/news?id=87afbbdfa3cf90f6fa9c2f1606b8e4e2815a41965d06fb3a2e23ca6b6f724d0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P 500 has gained 9.3%.",
                "category": "company",
                "datetime": 1783019304,
                "headline": "3 Reasons to Avoid CRL and 1 Stock to Buy Instead"
              },
              {
                "id": 140782807,
                "url": "https://finnhub.io/api/news?id=67d747b0e4de7ac62347615064d2cb439961b24f91a7a1a938f941d01938ecdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "LH vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782920405,
                "headline": "LH or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 140780947,
                "url": "https://finnhub.io/api/news?id=a7642c45e1a86a3113777b94e638cc282a04bf08bf074521d37c7dba7c1e84a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River leans on RMS strength, CRADL adoption and portfolio moves. Can these offset soft biopharma demand and currency headwinds?",
                "category": "company",
                "datetime": 1782912480,
                "headline": "Is This the Right Time to Hold CRL Stock in Your Portfolio?"
              },
              {
                "id": 140781615,
                "url": "https://finnhub.io/api/news?id=a41b497352b243f30385a2d53aefb1bce180e1468e1ef5bef606c5f068d620db",
                "image": "https://image.cnbcfm.com/api/v1/image/108328987-17828552841782855282-46874781825-1080pnbcnews.jpg?v=1782855283&w=1920&h=1080",
                "source": "CNBC",
                "related": "CRL",
                "summary": "CNBC's Angelica Peebles to talk Anthropic's new healthcare offering.",
                "category": "company",
                "datetime": 1782841349,
                "headline": "Anthropic launches Claude Science"
              },
              {
                "id": 140769645,
                "url": "https://finnhub.io/api/news?id=42ebca08725488bcaeb7da6f8764e5eef18c6f7dac01e2607f09e5a0cc3cdc75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2228869477/image_2228869477.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "U.S. equity markets were mixed this week, with weakness in growth and technology offset by strength in defensive and health care sectors. ",
                "category": "company",
                "datetime": 1782780900,
                "headline": "ValuEngine Weekly Market Summary And Commentary"
              },
              {
                "id": 140766943,
                "url": "https://finnhub.io/api/news?id=a194cc7fdd8513472493cedb2a6591abb4996822621a17b81ae2a5615648e3ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Is CRL a good stock to buy? We came across a bullish thesis on Charles River Laboratories International, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CRL. Charles River Laboratories International, Inc.’s share was trading at $202.10 as of June 24th. CRL’s trailing and forward P/E were 25.07 and 18.15 respectively […]",
                "category": "company",
                "datetime": 1782763617,
                "headline": "Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?"
              },
              {
                "id": 140781757,
                "url": "https://finnhub.io/api/news?id=5baed29654721b5d98fe3ce501ae03081ebb89e584dc62b245c3de70b534c11e",
                "image": "https://image.cnbcfm.com/api/v1/image/108262197-1770323920909-gettyimages-2260105869-bb1_2632_uxvikxrq.jpeg?v=1782775477&w=1920&h=1080",
                "source": "CNBC",
                "related": "CRL",
                "summary": "The Dow rose more than 300 points on Monday to post its first close above 52,000. Alphabet, a new addition to the 30-stock index, jumped almost 5%.",
                "category": "company",
                "datetime": 1782760725,
                "headline": "Tuesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140736422,
                "url": "https://finnhub.io/api/news?id=0670f579dfac7d1206e11eea64d3f7d776cb1650aed7eb2cdea372d7d40188d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "In June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab drug discovery platform. This collaboration ties Charles River more closely into Lilly’s Catalyze360 ecosystem, potentially deepening its role in data-rich, AI-enhanced preclinical research workflows. We’ll now examine how Charles River’s deeper integration into Lilly’s AI-driven...",
                "category": "company",
                "datetime": 1782482876,
                "headline": "Is Charles River (CRL) Quietly Redefining Its Moat Through Lilly’s AI-Driven TuneLab Collaboration?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 34,
            "discarded_article_count": 23
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.6,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(26.4%→11.2%)；跌縮量(近10日3日)；站上MA50；升放量(近10日3日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 875380,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 875420,
              "avg_vol_20": 932620,
              "avg_vol_30": 875380,
              "range_pct_10": 0.11232244681790093,
              "range_pct_20": 0.15919326507193923,
              "range_pct_30": 0.2644982346191191,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0000456944412712,
              "dist_to_20d_high": 0.05137119316009233,
              "down_shrink_days": 3,
              "breakout_level_20d": 238.85001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.42466236865303364
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 4.04334010062671,
              "turnoverUsdM": 107.874738,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 208.2572,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 8.1,
            "take_profit_price": 238.5509,
            "target_multiplier": 1.6,
            "technical_strength": 1.22,
            "take_profit_percent": 5.3
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 8.08668020125342,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 9.1614,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 4.04
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 22.58
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1591
    },
    "kdj": {
      "d": 42.67,
      "j": 48.24,
      "k": 44.53,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 43.77
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 3993800,
      "recentSlope": -154440,
      "previousSlope": 203870
    },
    "rsi": 45.16,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 232.7589,
      "position": "SAR喺價上",
      "distancePct": 2.73,
      "previousTrend": "下降"
    },
    "ma50": 196.691,
    "macd": {
      "macd": 7.318134657114513,
      "trend": "中性偏多",
      "signal": 9.559411079573543,
      "histogram": -2.2412764224590305
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 226.0356,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.54,
      "score": 2,
      "avgVolume": 879625,
      "currentVolume": 476100
    },
    "derived": {
      "ma20": 226.7665,
      "ma50": 196.691,
      "prevClose": 229.29,
      "avgVolume10": 835710,
      "avgVolume20": 879625,
      "changePercent": -1.18,
      "avgVolumeForScore": 879625
    },
    "ma_cross": {
      "ma20": 226.7665,
      "ma50": 196.691,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 226.073,
      "prevMa50": 195.5332,
      "spreadPct": 15.29,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 216.9105,
      "upper": 236.6225,
      "position": "中間"
    },
    "rsi_short": 44.57,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.54
    }
  }
}

{
  "close": 226.58,
  "volume": 476100,
  "changePercent": -1.18
}